Structure Therapeutics In... (GPCR)
25.34
0.18 (0.72%)
At close: Jan 14, 2025, 3:59 PM
26.00
2.60%
Pre-market Jan 15, 2025, 07:49 AM EST
undefined% (undefined)
| Bid | 25.5 |
| Market Cap | 1.45B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.16 |
| PE Ratio (ttm) | -11.73 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 27 |
| Volume | 1,119,124 |
| Avg. Volume (20D) | 838,432 |
| Open | 25.13 |
| Previous Close | 25.16 |
| Day's Range | 24.10 - 25.87 |
| 52-Week Range | 23.50 - 62.74 |
| Beta | undefined |
About GPCR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral sma...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 3, 2023
Employees 136
Stock Exchange NASDAQ
Ticker Symbol GPCR
Website https://structuretx.com
Analyst Forecast
According to 7 analyst ratings, the average rating for GPCR stock is "Buy." The 12-month stock price forecast is $80, which is an increase of 215.71% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
+1.03%
Structure Therapeutics shares are trading higher a...
Unlock content with
Pro Subscription
6 months ago ·
Source
-1.15%
Shares of weight loss stocks are trading lower, possibly on continued weakness following recent weight loss data from Roche, which could cause competition concerns for companies in the space.
